FOR IMMEDIATE RELEASE: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies SAN MARINO, Calif., Nov. 20, 2008 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth. Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma. About Epeius Biotechnologies Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com . *(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg) All trademarks are property of their respective owners. Send2Press(R) is the originating wire service for this story, Copr. 2008. NEWS SOURCE: Epeius Biotechnologies Corporation # # # // RELEASE END // MEDIA ONLY CONTACT(S): [ contact info below not for publication online or in print ] Erlinda M. Gordon, M.D. Epeius Biotechnologies Corporation Tel: +1-626-441-6695 egordon @ epeiusbiotech.com //Note to editors: For print-resolution logo/images contact the above person. Additional Epeius news and RSS feed: http://profiles.send2press.com/Epeius_Biotechnologies.shtml ......... Plain Text Copy, and Story Permalink: http://www.Send2Press.com/mediadrome/2008-11-1120-005P.txt Release PDF: http://www.Send2Press.com/mediadrome/news_2008-11-1120-005P.pdf Get our full-text news via RSS: http://www.Send2Press.com/RSS2/rss.xml ......... Text provided by news source (and/or the source's authorized agency), who is solely responsible for accuracy and legality of content transmitted. ......... This news story from Send2Press Newswire may be redistributed and re-posted in part or in whole by members of the media. Copr. (c) Send2Press, a unit of Neotrope(R). For news aggregation sites, blogs, and bureaus, you must retain Send2Press as the original wire service source. You may capture and self-host images linked to in above release, but do NOT stream from our server. ......... The original version of this release was issued on behalf of the above organization (the "news source"), by Send2Press(R) Newswire, a service of Neotrope(R). http://www.Send2Press.com. ......... NOVEMBER 2008 Press Release / B-NAT CA / IND: BUS BIO_MED DRUG TECH / agency = / ytv = / pre =